Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Drug: Selumetinib|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel
Sponsor: Russian Academy of Medical Sciences
Collaborators: Russian Society of Clinical Oncology